6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2015 (Report no. 1)

Commission File Number: 000-30820

TIKCRO TECHNOLOGIES LTD.

(Translation of registrant’s name into English)

98 Yigal Alon Street, 36th floor,

Tel Aviv, 6789141 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F xForm 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): N/A

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): N/A

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes oNo x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A

CONTENTS

This report on Form 6-K of the Registrant consists of the following documents, which are attached hereto and incorporated by reference herein:

Exhibit

Number Description of Exhibit

99.1 Press release: Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan, dated June 15, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIKCRO TECHNOLOGIES LTD.
	By:	/s/ Aviv Boim
Date: June 15, 2015		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Press release: Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan, dated June 15, 2015.

EX-99.1

Exhibit 99.1

For more information contact:	PRESS RELEASE
Investor Relations Jeff Corbin / Christopher Harrison KCSA Strategic Communications (212) 896-1214 / 1267 jcorbin@kcsa.com / charrison@kcsa.com

Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan

--Aims to accelerate pre-clinical development of functional antibodies--

Tel Aviv, Israel, June 15, 2015 - Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it will proceed with a pre-clinical plan for the generation and verification of new antibodies targeting the modulation of CTLA4 and PD1 cancer checkpoints.

Based on a novel approach, it is expected that such new antibodies will be generated and validated throughout 2015. These antibodies are expected to have greater specificity and binding qualities over existing antibodies.

CTLA4 and PD1 are acknowledged as key elements for harnessing a patient’s own immune system in cancer treatments. Antibodies targeting these checkpoints were approved for clinical use. Interim clinical results show strong synergistic benefit for a combination treatment of such antibodies.

Aviv Boim, CEO of Tikcro Technologies Ltd., commented: "Our plan directs the Company towards the development of new immuno-oncology antibody agents. We are promoting an innovative approach that aims to significantly accelerate and bring precise functional immune checkpoint antibodies from the design stage to clinical trials.”

Worldwide revenues for antibodies addressing these two checkpoints were $1.3 billion in 2014 and revenue estimates for 2015 are approximately $3.0 billion. Recent approvals of additional clinical indications and synergistic clinical effects for a combination treatment drive this expected increase.

About Tikcro Technologies:

Tikcro Technologies Ltd. (OTCQB: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. The Company is currently engaged with development of certain antibodies, selected and verified in pre-clinical trials with a focus on antibodies binding to cancer immune checkpoints PD1 and CTLA-4.

For more information about the Company, visit Tikcro’s website at www.tikcro.com.

Safe Harbor Statement

Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the risks related to early stage biotechnology projects, including, but not limited to, the development, testing, regulatory approval and commercialization, intellectual property rights, competition, exposure to lawsuits and dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Forms 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods.  We undertake no duty to update any forward-looking information.